EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Who Still Needs Surgery? Defining the Modern Surgical Phenotype in Inflammatory Bowel Disease

Taylor E Messick-Ngo, Kaitlin Boyer, Sophia Potalivo, Jasmine Kazemi Gwizdala iD, Gabriel Scally, Emily D Dubina iD, Nicholas Sheets, Aras Emdadi

The American Surgeon™ · 03.08.2026

DOI: 10.1177/00031348261474196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The American Surgeon™, online erschienen am 03.08.2026. Verfasst von Taylor E Messick-Ngo und 7 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery, Riverside Community Hospital, Riverside, CA, USA. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inflammatory bowel disease (IBD), affecting over 2 million individuals in the United States, is associated with substantial morbidity, recurrent hospitalizations, and need for long-term immunosuppressive therapy. Although biologic therapies have been associated with declining operative rates in IBD, a clinically significant subset of patients continues to progress to surgery despite biologic exposure.

Methods

This retrospective cohort study evaluated surgical intervention rates among patients with Crohn’s disease (CD) and ulcerative colitis (UC) across two biologic treatment eras using the TriNetX Research Network, a multi-institutional database of de-identified electronic health records. Adult patients (ages 18-90) receiving biologic therapy were divided into two cohorts: 2004-2014 and 2014-2024. Surgical intervention following biologic initiation was used as a surrogate for treatment failure, and propensity score matching was performed to reduce confounding.

Results

After matching, 9822 patients remained in each cohort. Surgical intervention occurred in 8.4% of patients in the earlier cohort compared with 5.9% in the contemporary cohort, corresponding to a 29.8% relative reduction in operative intervention (RR 1.426, 95% CI 1.285-1.583; P < 0.001). Patients in the earlier cohort also demonstrated significantly higher risk of surgery within 1 year of biologic initiation. Within the contemporary cohort, CD patients continued to demonstrate higher operative risk compared with UC.

Discussion

Contemporary biologic therapy was associated with reduced operative intervention over time; however, persistent operative burden remains despite biologic exposure, particularly among patients with CD and nutritional compromise.

Schlagwörter

Stichwörter der Autor:innen

Crohn’s diseasebiologic agentsgastrointestinalsurgical outcomesulcerative colitis

Autor:innen und Institutionen

  • General Surgery, Riverside Community Hospital, Riverside, CA, USA.
  • Riverside School of Medicine, University of California, Riverside, CA, USA.
  • Trauma and Acute Care Surgery, Riverside Community Hospital, Riverside, CA, USA.
  • Colorectal Surgery, Riverside Community Hospital, Riverside, CA, USA.

ORCID-Profile: Jasmine Kazemi Gwizdala, Emily D Dubina

Zitieren

APA

Messick-Ngo, T. E., Boyer, K., Potalivo, S., Gwizdala, J. K., Scally, G., Dubina, E. D., Sheets, N., & Emdadi, A. (2026). Who Still Needs Surgery? Defining the Modern Surgical Phenotype in Inflammatory Bowel Disease. The American Surgeon™. https://doi.org/10.1177/00031348261474196

Vancouver

Messick-Ngo TE, Boyer K, Potalivo S, Gwizdala JK, Scally G, Dubina ED, et al. Who Still Needs Surgery? Defining the Modern Surgical Phenotype in Inflammatory Bowel Disease. The American Surgeon™. 2026. doi:10.1177/00031348261474196

BibTeX
@article{MessickNgo2026,
  author = {Messick-Ngo, Taylor E and Boyer, Kaitlin and Potalivo, Sophia and Gwizdala, Jasmine Kazemi and Scally, Gabriel and Dubina, Emily D and Sheets, Nicholas and Emdadi, Aras},
  title = {Who Still Needs Surgery? Defining the Modern Surgical Phenotype in Inflammatory Bowel Disease},
  journal = {The American Surgeon™},
  year = {2026},
  doi = {10.1177/00031348261474196}
}
Kostenlos starten →